PHASE-I AND PHARMACOKINETIC EVALUATION OF FLOXURIDINE/LEUCOVORIN GIVEN ON THE ROSWELL-PARK WEEKLY REGIMEN

被引：2

作者：

CREAVEN, PJ

RUSTUM, YM

PETRELLI, NJ

MEROPOL, NJ

RAGHAVAN, D

RODRIGUEZBIGAS, M

LEVINE, EG

FRANK, C

UDVARYNAGY, S

PROEFROCK, A

机构：

[1] ROSWELL PK CANC INST,DIV EXPTL THERAPEUT,BUFFALO,NY 14263

[2] ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263

[3] ROSWELL PK CANC INST,DEPT SURG ONCOL,BUFFALO,NY 14263

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1994年 / 34卷 / 03期

关键词：

FLOXURIDINE; LEUCOVORIN; PHASE L;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase T and pharmacokinetics study was carried out of floxuridine (FdUrd) modulated by leucovorin (LV) given on the Roswell Park regimen (LV given at 500 mg/m(2) by 2-h infusion and FdUrd given by i. v. push at 1 h after the start of LV infusion, treatment being given weekly x 6). The dose-limiting toxicity was diarrhea; the MTD and recommended dose for phase II studies was 1,650 mg/m(2) per week of FdUrd. The dose-response curve was steep, with 3/3 patients treated at a dose of 1,750 mg/ m(2) developing grade IV diarrhea. With this schedule there was no significant mucositis. Pharmacokinetic parameters showed very wide interpatient variability. Plasma decay was biphasic with a t(1/2)beta of approximately 2 h. Plasma clearance was high (> 200 1 h(-1)). No correlation between pharmacokinetic parameters and toxicity could be identified.

引用

页码：261 / 265

页数：5